The Evolution of Capital Management with Timothy Armour

Timothy Armour is an investor with more than 30 years of experience to draw from in his everyday life. As soon as Mr. Armour graduated high school, he applied for and was accepted into Middlebury College. While he was studying there, Timothy Armour obtained his bachelor’s degree in the field of economics.

 

Early Career

Timothy Armour began his career with accepting a position at Capital Research and Management through The Associates Program. He worked his way up through the company over 30 years. Mr. Armour has covered a variety of positions at Capital Research and Management. Earlier in his career, he covered telecommunications on a global level as an equity investment analyst and Timothy’s lacrosse camp.

 

Timothy Armour Appointed Chairman of Capital Group

In mid-2015, Capital Group lost it’s Chairman Jim Rothenberg at the age of 69. Timothy Armour was named to take his place, but there had been succession paperwork and preparations being made for years before Mr. Rothenberg’s passing. This promotion puts Mr. Armour at the top of the company that is widely considered one of the leading investment portfolio businesses in the world.

 

Capital Group and Samsung Asset Management

Capital Group made the strategic move to align themselves with Samsung Asset Management in late 2015. The goal of this partnership is to develop investment strategies for businesses in Korea, where Samsung Asset Management is based. Timothy Armour stated Capital Group would help Samsung Asset Management become more familiar with active management, and this will be tailored after Capital Group’s model and learn more about Timothy.

 

Timothy Armour is a well-known businessman who will continue to evolve to meet the demands of the customer. His long career ensures he has the experience to do many successful mergers and investment opportunities in the future. Capital Group will continue to be a global powerhouse on the investment front and more information click here.

 

Other Reference: https://en.wikipedia.org/wiki/Capital_Group_Companies

Dr. Siegall Clay Leads Seattle Genetics into the Search for Working Cancer Cures

Many companies are trying their best to find a cure for cancer. It’s been so for many years and many a researchers are coming up with impressive findings. One of the companies that has joined the search is Seattle Genetics, a biotechnology company that is currently under the leadership of Siegall Clay. In a recent event, the company impressed those in attendance with its breathtaking advancements in cancer therapy advancement.

It is evident to see how the company has been growing over the past five years with how much its stock has been rising. The fact that the stick has tripled over five years is an indication of how much of an industry leader Seattle Genetics is.

About Dr. Siegall Clay

Dr. Siegall is the current CEO of Seattle Genetics. He has a passion for improving the lives of cancer patients from the time he got into biomedical studies. He is also the president and chairperson of the board of Seattle Genetics. He has been serving under the position of the chief executive officer in the company from 2002. He has been with the company for close to two decades ever since he cofounded it in 1998. From the company’s inception, Dr. Clay Siegall has worked and dedicated himself to the company’s success with specialty in cancer therapy treatments and cancer patients care.

Achievements

Dr. Siegall is known for amazing significant awards for his contribution in cancer patients’ care and treatment. His career started in Bristol Meyers as a researcher. His position of senior research investigator helped him to gain information that led him to heading Seattle Genetics.

About Seattle Genetics

Seattle Genetics is a prolific biotechnology company focusing on developing and commercializing innovative cancer remedies based on antibodies. As an industry leader in antibody-drug conjugates, Seattle Genetics is at the forefront when it comes to developing solutions that leverage the targeting powers of monocional antibodies. Seattle Genetics seeks to innovate a cure that will take the fight straight to the targeted cancerous cells without harming neighboring healthy cells. This is the closest we’ve got almost passive medication that will not dire side effects like traditional chemotherapy and radiotherapy.

 

Categories: CEO